Nanomedicinal delivery of stimulator of interferon genes agonists: Recent advances in virus vaccination

Saborni Chattopadhyay, Che Ming Jack Hu

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


The discovery of stimulator of interferon genes (STING) and their agonists as primary components that link antiviral innate and adaptive immunity has motivated growing research on STING agonist-mediated immunotherapy and vaccine development. To overcome the delivery challenge in shuttling highly polar STING agonists, typically in the form of cyclic dinucleotides, to target cells and to STING proteins in cellular cytosol, numerous nanoformulation strategies have been implemented for effective STING activation. While many STING-activating nanoparticles are developed to enhance anticancer immunotherapy, their adoption as vaccine adjuvant has vastly propelled antiviral vaccination efforts against challenging public health threats, including HIV, influenza and coronaviruses. In light of the COVID-19 pandemic that has thrusted vaccine development into the public spotlight, this review highlights advances in nanomedicinal STING agonist delivery with an emphasis on their applications in antiviral vaccination.

Original languageEnglish
Pages (from-to)2883-2894
Number of pages12
Issue number29
Publication statusPublished - 2020 Dec

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)


Dive into the research topics of 'Nanomedicinal delivery of stimulator of interferon genes agonists: Recent advances in virus vaccination'. Together they form a unique fingerprint.

Cite this